<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31519910</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>13</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>The mutational landscape of a prion-like domain.</ArticleTitle><Pagination><StartPage>4162</StartPage><MedlinePgn>4162</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4162</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-019-12101-z</ELocationID><Abstract><AbstractText>Insoluble protein aggregates are the hallmarks of many neurodegenerative diseases. For example, aggregates of TDP-43 occur in nearly all cases of amyotrophic lateral sclerosis (ALS). However, whether aggregates cause cellular toxicity is still not clear, even in simpler cellular systems. We reasoned that deep mutagenesis might be a powerful approach to disentangle the relationship between aggregation and toxicity. We generated &gt;50,000 mutations in the prion-like domain (PRD) of TDP-43 and quantified their toxicity in yeast cells. Surprisingly, mutations that increase hydrophobicity and aggregation strongly decrease toxicity. In contrast, toxic variants promote the formation of dynamic liquid-like condensates. Mutations have their strongest effects in a hotspot that genetic interactions reveal to be structured in vivo, illustrating how mutagenesis can probe the in vivo structures of unstructured proteins. Our results show that aggregation of TDP-43 is not harmful but protects cells, most likely by titrating the protein away from a toxic liquid-like phase.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bolognesi</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Doctor Aiguader 88, 08003, Barcelona, Spain. bbolognesi@ibecbarcelona.eu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Barcelona, Spain. bbolognesi@ibecbarcelona.eu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faure</LastName><ForeName>Andre J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0002-4471-5994</Identifier><AffiliationInfo><Affiliation>Center for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Doctor Aiguader 88, 08003, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seuma</LastName><ForeName>Mireia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Doctor Aiguader 88, 08003, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmiedel</LastName><ForeName>J&#xf6;rn M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Center for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Doctor Aiguader 88, 08003, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tartaglia</LastName><ForeName>Gian Gaetano</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>Center for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Doctor Aiguader 88, 08003, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Pompeu Fabra (UPF), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituci&#xf3; Catalana de Recerca i Estudis Avan&#xe7;ats (ICREA), Passeig Llu&#xed;s Companys 23, 08010, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology 'Charles Darwin', Sapienza University of Rome, P.le A. Moro 5, Rome, 00185, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehner</LastName><ForeName>Ben</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-8817-1124</Identifier><AffiliationInfo><Affiliation>Center for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Doctor Aiguader 88, 08003, Barcelona, Spain. ben.lehner@crg.eu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Pompeu Fabra (UPF), Barcelona, Spain. ben.lehner@crg.eu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituci&#xf3; Catalana de Recerca i Estudis Avan&#xe7;ats (ICREA), Passeig Llu&#xed;s Companys 23, 08010, Barcelona, Spain. ben.lehner@crg.eu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057927" MajorTopicYN="N">Hydrophobic and Hydrophilic Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049490" MajorTopicYN="N">Systems Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31519910</ArticleId><ArticleId IdType="pmc">PMC6744496</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-12101-z</ArticleId><ArticleId IdType="pii">10.1038/s41467-019-12101-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Buratti, E. Functional Significance of TDP-43 Mutations in Disease. Adv. Genet.&#xa0;91, 1&#x2013;53 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26410029</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling S-C, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Stefani M, Taddei N, Ramponi G, Dobson CM. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature. 2003;424:805&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">12917692</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg D, Jucker M. The amyloid state of proteins in human diseases. Cell. 2012;148:1188&#x2013;1203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3353745</ArticleId><ArticleId IdType="pubmed">22424229</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006;75:333&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">16756495</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson&#x2019;s disease. Science. 1997;276:2045&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold ES, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc. Natl Acad. Sci. USA. 2013;110:E736&#x2013;E745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3581922</ArticleId><ArticleId IdType="pubmed">23382207</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539:197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon D, et al. Single-copy expression of an amyotrophic lateral sclerosis-linked TDP-43 mutation (M337V) in BAC transgenic mice leads to altered stress granule dynamics and progressive motor dysfunction. Neurobiol. Dis. 2019;121:148&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">30290270</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Lessons from a failed &#x3b3;-secretase Alzheimer trial. Cell. 2014;159:721&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">25417150</ArticleId></ArticleIdList></Reference><Reference><Citation>Karran E, Mercken M, Strooper BD. The amyloid cascade hypothesis for Alzheimer&#x2019;s disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 2011;10:698.</Citation><ArticleIdList><ArticleId IdType="pubmed">21852788</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13:1127&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316019</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolognesi B, et al. ANS binding reveals common features of cytotoxic amyloid species. ACS Chem. Biol. 2010;5:735&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pubmed">20550130</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremades N, et al. Direct observation of the interconversion of normal and toxic forms of &#x3b1;-synuclein. Cell. 2012;149:1048&#x2013;1059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383996</ArticleId><ArticleId IdType="pubmed">22632969</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y-S, et al. Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients. Nat. Commun. 2014;5:4824.</Citation><ArticleIdList><ArticleId IdType="pubmed">25215604</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu C, Beck MV, Griffith JD, Deshmukh M, Dokholyan NV. Large SOD1 aggregates, unlike trimeric SOD1, do not impact cell viability in a model of amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA. 2018;115:4661&#x2013;4665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5939103</ArticleId><ArticleId IdType="pubmed">29666246</ArticleId></ArticleIdList></Reference><Reference><Citation>Escusa-Toret S, Vonk WIM, Frydman J. Spatial sequestration of misfolded proteins by a dynamic chaperone pathway enhances cellular fitness during stress. Nat. Cell Biol. 2013;15:1231&#x2013;1243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4121856</ArticleId><ArticleId IdType="pubmed">24036477</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateju, D. et al. An aberrant phase transition of stress granules triggered by misfolded protein and prevented by chaperone function. EMBO J. 36, 1669&#x2013;1687 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5470046</ArticleId><ArticleId IdType="pubmed">28377462</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberti S, Hyman AA. Are aberrant phase transitions a driver of cellular aging? Bioessays. 2016;38:959&#x2013;968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5108435</ArticleId><ArticleId IdType="pubmed">27554449</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan T, et al. Quantifying nucleation in vivo reveals the physical basis of prion-like phase behavior. Mol. Cell. 2018;71:155&#x2013;168.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6086602</ArticleId><ArticleId IdType="pubmed">29979963</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, et al. Nuclear-import receptors reverse aberrant phase transitions of RNA-binding proteins with prion-like domains. Cell. 2018;173:677&#x2013;692.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5911940</ArticleId><ArticleId IdType="pubmed">29677512</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzmann, T. M. et al. Phase separation of a yeast prion protein promotes cellular fitness. Science359, eaao5654 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29301985</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, et al. A molecular grammar governing the driving forces for phase separation of prion-like RNA binding proteins. Cell. 2018;174:688&#x2013;699.e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6063760</ArticleId><ArticleId IdType="pubmed">29961577</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A, et al. A liquid-to-solid phase transition of the ALS protein FUS accelerated by disease mutation. Cell. 2015;162:1066&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">26317470</ArticleId></ArticleIdList></Reference><Reference><Citation>Molliex A, et al. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell. 2015;163:123&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5149108</ArticleId><ArticleId IdType="pubmed">26406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegmann, S. et al. Tau protein liquid-liquid phase separation can initiate tau aggregation. EMBO J. 37, e98049 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5881631</ArticleId><ArticleId IdType="pubmed">29472250</ArticleId></ArticleIdList></Reference><Reference><Citation>Vavouri T, Semple JI, Garcia-Verdugo R, Lehner B. Intrinsic protein disorder and interaction promiscuity are widely associated with dosage sensitivity. Cell. 2009;138:198&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">19596244</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolognesi B, et al. A concentration-dependent liquid phase separation can cause toxicity upon increased protein expression. Cell Rep. 2016;16:222&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4929146</ArticleId><ArticleId IdType="pubmed">27320918</ArticleId></ArticleIdList></Reference><Reference><Citation>Halfmann R, et al. Opposing effects of glutamine and asparagine govern prion formation by intrinsically disordered proteins. Mol. Cell. 2011;43:72&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3132398</ArticleId><ArticleId IdType="pubmed">21726811</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi S, et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer&#x2019;s disease and dementia with Lewy bodies. Brain Res. 2007;1184:284&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">17963732</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab C, Arai T, Hasegawa M, Yu S, McGeer PL. Colocalization of transactivation-responsive DNA-binding protein 43 and Huntingtin in inclusions of Huntington disease. J. Neuropathol. Exp. Neurol. 2008;67:1159&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">19018245</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x2019;s disease. Ann. Neurol. 2007;61:435&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchino A, et al. Incidence and extent of TDP-43 accumulation in aging human brain. Acta Neuropathol. Commun. 2015;3:35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4473839</ArticleId><ArticleId IdType="pubmed">26091809</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L-L, et al. Structural transformation of the amyloidogenic core region of TDP-43 protein initiates its aggregation and cytoplasmic inclusion. J. Biol. Chem. 2013;288:19614&#x2013;19624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707662</ArticleId><ArticleId IdType="pubmed">23689371</ArticleId></ArticleIdList></Reference><Reference><Citation>Conicella AE, Zerze GH, Mittal J, Fawzi NL. ALS mutations disrupt phase separation mediated by &#x3b1;-helical structure in the TDP-43 low-complexity C-terminal domain. Struct./Fold. Des. 2016;24:1537&#x2013;1549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014597</ArticleId><ArticleId IdType="pubmed">27545621</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Chakrabartty A. Phase to phase with TDP-43. Biochemistry. 2017;56:809&#x2013;823.</Citation><ArticleIdList><ArticleId IdType="pubmed">28112502</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt, H. B., Barreau, A. &amp; Rohatgi, R. Decoding and recoding phase behavior of TDP43 reveals that phase separation is not required for splicing function. Preprint at https://www.biorxiv.org/content/10.1101/548339v1 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/548339v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Babinchak, W. M. et al. The role of liquid-liquid phase separation in aggregation of the TDP-43 low complexity domain. J. Biol. Chem. (2019). 10.1074/jbc.RA118.007222</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6484124</ArticleId><ArticleId IdType="pubmed">30814253</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou, C.-C. et al. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat. Neurosci. 21, 228&#x2013;239 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800968</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk, L. et al. Poly(ADP-Ribose) Prevents pathological phase separation of TDP-43 by promoting liquid demixing and stress granule localization. Mol. Cell71, 703&#x2013;717&#xa0;(2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6128762</ArticleId><ArticleId IdType="pubmed">30100264</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne, A. N. et al. Fragile X protein mitigates TDP-43 toxicity by remodeling RNA granules and restoring translation. Hum. Mol. Genet. 24, 6886&#x2013;6898 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5007633</ArticleId><ArticleId IdType="pubmed">26385636</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa, F. et al. Cytoplasmic TDP-43 de-mixing independent of stress granules drives inhibition of nuclear import, loss of nuclear TDP-43, and cell death. Neuron&#xa0;102, 339&#x2013;357 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Alton S, et al. Divergent phenotypes in mutant TDP-43 transgenic mice highlight potential confounds in TDP-43 transgenic modeling. PLoS ONE. 2014;9:e86513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3899264</ArticleId><ArticleId IdType="pubmed">24466128</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann, J. R. et al. RNA binding antagonizes neurotoxic phase transitions of TDP-43. Neuron&#xa0;102,&#xa0;321&#x2013;338 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L-L, et al. Two mutations G335D and Q343R within the amyloidogenic core region of TDP-43 influence its aggregation and inclusion formation. Nat. Publ. Group. 2016;6:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4814915</ArticleId><ArticleId IdType="pubmed">27030292</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler DM, Fields S. Deep mutational scanning: a new style of protein science. Nat. Methods. 2014;11:801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4410700</ArticleId><ArticleId IdType="pubmed">25075907</ArticleId></ArticleIdList></Reference><Reference><Citation>Staller MV, et al. A high-throughput mutational scan of an intrinsically disordered acidic transcriptional activation domain. Cell Syst. 2018;6:444&#x2013;455.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5920710</ArticleId><ArticleId IdType="pubmed">29525204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravarani CN, et al. High-throughput discovery of functional disordered regions: investigation of transactivation domains. Mol. Syst. Biol. 2018;14:e8190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5949888</ArticleId><ArticleId IdType="pubmed">29759983</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmiedel JM, Lehner B. Determining protein ptructure using genetics. Nat. Genet. 2019;51:1177&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pubmed">31209395</ArticleId></ArticleIdList></Reference><Reference><Citation>Guenther EL, et al. Atomic structures of TDP-43 LCD segments and insights into reversible or pathogenic aggregation. Nat. Struct. Mol. Biol. 2018;25:463&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5990464</ArticleId><ArticleId IdType="pubmed">29786080</ArticleId></ArticleIdList></Reference><Reference><Citation>Mompe&#xe1;n M, et al. Structural evidence of amyloid fibril formation in the putative aggregation domain of TDP-43. J. Phys. Chem. Lett. 2015;6:2608&#x2013;2615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5568655</ArticleId><ArticleId IdType="pubmed">26266742</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, et al. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J. Biol. Chem. 2009;284:20329&#x2013;20339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, McCaffery JM, Lindquist S, Gitler AD. A yeast TDP-43 proteinopathy model: exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc. Natl Acad. Sci. USA. 2008;105:6439&#x2013;6444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2359814</ArticleId><ArticleId IdType="pubmed">18434538</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamaki Y, et al. Elimination of TDP-43 inclusions linked to amyotrophic lateral sclerosis by a misfolding-specific intrabody with dual proteolytic signals. Sci. Rep. 2018;8:6030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5902603</ArticleId><ArticleId IdType="pubmed">29662239</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrawell, N. E. et al. Distinct partitioning of ALS associated TDP-43, FUS and SOD1 mutants into cellular inclusions. Sci. Rep. 5, 13416 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544019</ArticleId><ArticleId IdType="pubmed">26293199</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaganovich D, Kopito R, Frydman J. Misfolded proteins partition between two distinct quality control compartments. Nature. 2008;454:1088&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746971</ArticleId><ArticleId IdType="pubmed">18756251</ArticleId></ArticleIdList></Reference><Reference><Citation>Peskett TR, et al. A liquid to solid phase transition underlying pathological Huntingtin Exon1 aggregation. Mol. Cell. 2018;70:588&#x2013;601.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5971205</ArticleId><ArticleId IdType="pubmed">29754822</ArticleId></ArticleIdList></Reference><Reference><Citation>Rollins NJ, et al. Inferring protein 3D structure from deep mutation scans. Nat. Genet. 2019;51:1170&#x2013;1176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7295002</ArticleId><ArticleId IdType="pubmed">31209393</ArticleId></ArticleIdList></Reference><Reference><Citation>Toth-Petroczy A, et al. Structured states of disordered proteins from genomic sequences. Cell. 2016;167:158&#x2013;170.e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5451116</ArticleId><ArticleId IdType="pubmed">27662088</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes MP, et al. Atomic structures of low-complexity protein segments reveal kinked &#x3b2; sheets that assemble networks. Science. 2018;359:698&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6192703</ArticleId><ArticleId IdType="pubmed">29439243</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim L, Wei Y, Lu Y, Song J. ALS-causing mutations significantly perturb the self-assembly and interaction with nucleic acid of the intrinsically disordered prion-like domain of TDP-43. PLoS Biol. 2016;14:e1002338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4703307</ArticleId><ArticleId IdType="pubmed">26735904</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Dobson CM. Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu. Rev. Biochem. 2017;86:27&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">28498720</ArticleId></ArticleIdList></Reference><Reference><Citation>Armakola M, et al. Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nat. Publ. Group. 2012;44:1302&#x2013;1309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3510335</ArticleId><ArticleId IdType="pubmed">23104007</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisberg SJ, et al. Compartmentalization of superoxide dismutase 1 (SOD1G93A) aggregates determines their toxicity. Proc. Natl Acad. Sci. USA. 2012;109:15811&#x2013;15816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3465386</ArticleId><ArticleId IdType="pubmed">22967507</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431:805&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">15483602</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J. Mammalian prions and their wider relevance in neurodegenerative diseases. Nature. 2016;539:217&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">27830781</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles TPJ, Vendruscolo M, Dobson CM. The amyloid state and its association with protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 2014;15:384&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">24854788</ArticleId></ArticleIdList></Reference><Reference><Citation>Karran E, De Strooper B. The amyloid cascade hypothesis: are we poised for success or failure? J. Neurochem. 2016;139:237&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">27255958</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, et al. Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. Neurology. 2010;75:619&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pubmed">20702794</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, et al. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS ONE. 2012;7:e37885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3371007</ArticleId><ArticleId IdType="pubmed">22715372</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitzman JO, Starita LM, Lo RS, Fields S, Shendure J. Massively parallel single-amino-acid mutagenesis. Nat. Methods. 2015;12:203&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4344410</ArticleId><ArticleId IdType="pubmed">25559584</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapsomaniki MA, et al. easyFRAP: an interactive, easy-to-use tool for qualitative and quantitative analysis of FRAP data. Bioinformatics. 2012;28:1800&#x2013;1801.</Citation><ArticleIdList><ArticleId IdType="pubmed">22543368</ArticleId></ArticleIdList></Reference><Reference><Citation>Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010;26:2460&#x2013;2461.</Citation><ArticleIdList><ArticleId IdType="pubmed">20709691</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>